About US
Contact us
-
Lundbeck secures rights to IBC's research for Alzheimer's treatmentDanish pharmaceutical company Lundbeck has signed an agreement to secure the rights of biotech firm ImmunoBrain Checkpoint’s (IBC) breakthrough research in Alzheimer's disease treatment. The research2017/7/18
-
Merck and F-star to develop five bispecific immuno-oncology antibodiesGerman science and technology firm Merck has entered a new strategic collaboration with UK-based biopharmaceutical firm F-star to develop and commercialise five bispecific immuno-oncology antibodies.2017/7/18
-
Novartis and IBM Watson to optimise cancer care and patient outcomesNovartis has partnered with IBM Watson Health on an outcome-based initiative for patients with advanced breast cancer. The collaboration will involve research on a cognitive solution that uses real-w2017/7/17
-
Innate Pharma acquires anti-C5aR antibody from Novo NordiskFrench biotechnology company Innate Pharma has signed an agreement to acquire a clinical-stage anti-C5a receptor (C5aR) antibody (IPH5401) from Danish pharmaceutical firm Novo Nordisk for €40m. The m2017/7/17
-
UK CMA accuses Merck of breaking competition law with discount schemeThe UK Competition and Markets Authority (CMA) has accused US pharmaceutical company Merck Sharp & Dohme(MSD) of operating an anti-competitive discount scheme for its medicine Remicade. Remicade2017/7/14
-
AC Immune and Essex to develop biological treatment for neurodegenerative diseasesAC Immune and Essex Bio-Technology have signed a research collaboration agreement to conduct a pre-clinical study and clinical codevelopment of a novel biological therapeutic to treat neurodegenerativ2017/7/13
-
Cancer Research UK funded scientists to test Zika virus on brain tumoursScientists funded by Cancer Research UK will investigate the effectiveness of the Zika virus in destroying brain tumour cells, which could lead to new treatments for cancer. Under the initiative, Dr2017/7/11
-
J&J completes Actelion acquisition for $30bnJohnson & Johnson (J&J) has completed the acquisition of Actelion Pharmaceuticals for approximately $30bn in an all-cash transaction through its Swiss subsidiary Janssen Holding. The European2017/7/8
-
Integral Molecular begins immuno-oncology therapeutic targets discoveryUS-based research-driven biotechnology company Integral Molecular has begun a therapeutic target discovery programme in immuno-oncology by utilising its membrane proteome array technology to identify2017/7/7
-
Boehringer opens biopharmaceutical manufacturing facility in ChinaGermany’s Boehringer Ingelheim has officially opened its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park in Shanghai, China. The facilitycarries a first-phase investment2017/7/6